iSTAR Medical has introduced its MINIject device for the treatment of patients with glaucoma, in the Netherlands.

The latest development is part of its strategy to expand the device availability in the European region.

As part of the device introduction in the region, the company successfully carried out the first device implantations for glaucoma patients at the University Eye Clinic of the Maastricht University Medical Center+ in the country.

A bio-integrating, minimally invasive glaucoma surgery (MIGS) device, MINIject is intended to treat primary open-angle glaucoma, a key cause of permanent blindness.

The device leverages the potential of the distinguished porous structure of its STAR material in the supraciliary space.

It aids in boosting the usual outflow of fluid, lowering intraocular pressure (IOP) and dependency on treatments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

This approach aids in the bio-integration of nearby tissues to lower inflammation, fibrosis and ensuing problems.

MINIject is claimed to have demonstrated robust and lasting results in cutting down IOP with an encouraging safety profile.

The deployment of MINIject device in the Netherlands complements its current product portfolio offered across Europe.

iSTAR’s MINIject is currently approved in the European region to treat open-angle glaucoma. The company now plans to obtain market approval for the device in the US soon. 

iSTAR Medical CEO Michel Vanbrabant said: “iSTAR Medical continues to make significant progress in the global commercial rollout of MINIject and I am proud with this achievement in the Netherlands to close 2023. 

“We would like to extend our thanks to the team at the University Eye Clinic of the Maastricht University Medical Center+ for completing the first surgeries and for their contribution towards achieving our aim of improving the lives of people around the world affected by glaucoma.” 

In July 2022, iSTAR Medical entered into a strategic partnership with AbbVie to advance the development and marketing of MINIject for glaucoma.

This deal is intended to aid iSTAR in the development and commercial activities linked to MINIject as well as offer the potential for AbbVie to bolster its eye care business.